Going to throw this out there purely for S & G's...
MRNA $26.49
Common stock, par value $0.0001; 1,600,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 332,494,777 and 328,798,904 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively
IPIX $0.1030
Common Stock - Class A, $0.0001 par value, 600,000,000 shares and 300,000,000 shares authorized, as of December 31, 2019 and June 30, 2019, respectively, 219,211,111 shares and 202,860,141 shares issued as of December 31, 2019 and June 30, 2019, respectively, 218,551,663 shares and 202,631,923 shares outstanding as of December 31, 2019 and June 30, 2019, respectively
Brilacidin makes the headlines from their lab testing... well, I sure as hell wouldn't want to be on the sidelines.
Guess we should consider how much FURTHER AHEAD IPIX is as well. Brilacidin has already PROVEN safety in humans.
MRNA $26.49
Common stock, par value $0.0001; 1,600,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 332,494,777 and 328,798,904 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively
IPIX $0.1030
Common Stock - Class A, $0.0001 par value, 600,000,000 shares and 300,000,000 shares authorized, as of December 31, 2019 and June 30, 2019, respectively, 219,211,111 shares and 202,860,141 shares issued as of December 31, 2019 and June 30, 2019, respectively, 218,551,663 shares and 202,631,923 shares outstanding as of December 31, 2019 and June 30, 2019, respectively
Brilacidin makes the headlines from their lab testing... well, I sure as hell wouldn't want to be on the sidelines.
Guess we should consider how much FURTHER AHEAD IPIX is as well. Brilacidin has already PROVEN safety in humans.
8
